39,493 Shares in Royalty Pharma plc (NASDAQ:RPRX) Purchased by Qsemble Capital Management LP

Qsemble Capital Management LP bought a new position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm bought 39,493 shares of the biopharmaceutical company's stock, valued at approximately $1,117,000.

Several other institutional investors and hedge funds have also made changes to their positions in RPRX. Versant Capital Management Inc lifted its position in Royalty Pharma by 5,215.0% during the second quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 1,043 shares in the last quarter. Gladius Capital Management LP purchased a new position in shares of Royalty Pharma during the 2nd quarter worth $32,000. Blue Trust Inc. boosted its position in shares of Royalty Pharma by 362.7% during the 3rd quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 943 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Royalty Pharma by 32.1% in the second quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 655 shares during the period. Finally, iA Global Asset Management Inc. grew its holdings in shares of Royalty Pharma by 274.7% in the second quarter. iA Global Asset Management Inc. now owns 6,388 shares of the biopharmaceutical company's stock valued at $168,000 after purchasing an additional 4,683 shares during the period. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have weighed in on RPRX. The Goldman Sachs Group boosted their target price on shares of Royalty Pharma from $50.00 to $51.00 and gave the company a "buy" rating in a report on Wednesday, August 14th. Citigroup decreased their price target on Royalty Pharma from $60.00 to $40.00 and set a "buy" rating on the stock in a research note on Friday, October 25th. Finally, StockNews.com raised shares of Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $41.67.

Royalty Pharma Price Performance

RPRX stock opened at $26.29 on Wednesday. The business's fifty day moving average price is $27.22 and its 200 day moving average price is $27.35. Royalty Pharma plc has a 12-month low of $25.10 and a 12-month high of $31.66. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $15.49 billion, a PE ratio of 13.62, a P/E/G ratio of 4.65 and a beta of 0.47.

Royalty Pharma Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a dividend of $0.21 per share. The ex-dividend date is Friday, November 15th. This represents a $0.84 dividend on an annualized basis and a yield of 3.20%. Royalty Pharma's dividend payout ratio (DPR) is presently 43.52%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.